

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Robert Reiter et al.	Examiner:	Dr. Larry Helms
Serial No.:	Not yet known	Group Art Unit:	1642
Filed:	Herewith		
Title:	PSCA: PROSTATE STEM CELL ANTIGEN AND USES THEREOF		

35 N. Arroyo Parkway, #60
Pasadena, California 91103
May 14, 2001

Assistant Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

SIR:

PRELIMINARY AMENDMENT

Please amend the subject application as follows.

In the Specification:

Please replace the paragraph beginning at page 1, line 5 with the following rewritten paragraph:

-- This application is a Divisional application of U. S. Serial No. 09/564,329, filed May 3, 2000, which is a CIP of U.S. Serial No. 09/359,326, filed July 20, 1999, which is a CIP of U.S. Serial No. 09/318,503, filed May 25, 1999, which is a CIP of U.S. Serial No. 09/251,835, filed February 17, 1999, which is a CIP of U.S. Serial No. 09/203,939, filed December 2, 1998, which is a CIP of U.S. Serial No. 09/038,261, filed March 10, 1998; claiming the priority of provisional applications, U.S. Serial No. 60/228,816, filed March

10, 1997; U. S. Serial No. 60/071,141 filed January 12, 1998 and; U. S. Serial No. 60/074,675, filed February 13, 1998. This application further claims the benefit of the filing dates of U.S. Serial No. 60/113,230 filed December 21, 1998, U.S. Serial No. 60/120,536 filed February 17, 1999, and U.S. Serial No. 60/124,658 filed March 16, 1999. The contents of all of the foregoing applications are incorporated by reference into the present application. --

Please replace the paragraph beginning at page 6, line 13 with the following rewritten paragraph:

-- **FIG. 1A.** Nucleotide sequence (SEQ ID NO:1, ATCC Designation 209612) of a cDNA encoding human PSCA.

FIG. 1B. Translated amino acid sequence (SEQ ID NO:2) of human PSCA. -- .

Please replace the paragraph beginning at page 6, line 16 with the following rewritten paragraph:

-- **FIG. 2.** Nucleotide sequence (SEQ ID NO:3), of a murine cDNA PSCA homologue and the translated amino acid sequence (SEQ ID NO:4) of murine PSCA. -- .

IN THE CLAIMS:

Please cancel claims 2-52, without prejudice to pursue the subject matter of these claims in a related application.

Please add new claims 53-86 as follows:

-- 53. (NEW) An anti-idiotypic antibody which binds to an antibody which binds to a Prostate Stem Cell Antigen (PSCA) protein or a portion thereof. --

- 54. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA protein so bound comprises amino acid residues 1 through 123 as described in SEQ ID NO:2. --
- 55. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 2 through 50 as described in SEQ ID NO:2. --
- 56. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 85 through 123 as described in SEQ ID NO:2. --
- 57. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 46 through 109 as described in SEQ ID NO:2. --
- 58. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 18 through 98 as described in SEQ ID NO:2. --
- 59. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 22 through 99 as described in SEQ ID NO:2. --
- 60. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 21 through 50 as described in SEQ ID NO:2. --
- 61. (NEW) The anti-idiotypic antibody of claim 53 wherein the PSCA so bound comprises amino acid residues 46 through 85 as described in SEQ ID NO:2. --
- 62. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound by the antibody which binds to a Prostate Stem Cell Antigen (PSCA) comprises amino acid residues 50 through 64 as described in SEQ ID NO:2. --

- 63. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 67 through 81 as described in SEQ ID NO:2. --
- 64. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 21 through 99 as described in SEQ ID NO:2. --
- 65. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 71 through 82 as described in SEQ ID NO:2. --
- 66. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 85 through 99 as described in SEQ ID NO:2. --
- 67. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 18 through 50 as described in SEQ ID NO:2. --
- 68. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 46 through 98 as described in SEQ ID NO:2. --
- 69. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 85 through 98 as described in SEQ ID NO:2. --
- 70. (NEW) A method for inducing an immune response in a subject, comprising administering to the subject the anti-idiotypic PSCA antibody of claim 53. --
- 71. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 1 through 123 of PSCA as described in SEQ ID NO:2. --

- 72. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 2 through 50 of PSCA as described in SEQ ID NO:2. --
- 73. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 85 through 123 of PSCA as described in SEQ ID NO:2. --
- 74. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 46 through 109 of PSCA as described in SEQ ID NO:2. --
- 75. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 18 through 98 of PSCA as described in SEQ ID NO:2. --
- 76. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 22 through 99 of PSCA as described in SEQ ID NO:2. --
- 77. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 21 through 50 of PSCA as described in SEQ ID NO:2. --
- 78. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 46 through 85 of PSCA as described in SEQ ID NO:2. --

- 79. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 50 through 64 of PSCA as described in SEQ ID NO:2. --
- 80. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 67 through 81 of PSCA as described in SEQ ID NO:2. --
- 81. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 21 through 99 of PSCA as described in SEQ ID NO:2. --
- 82. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 71 through 82 of PSCA as described in SEQ ID NO:2. --
- 83. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 85 through 99 of PSCA as described in SEQ ID NO:2. --
- 84. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 18 through 50 of PSCA as described in SEQ ID NO:2. --
- 85. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 46 through 98 of PSCA as described in SEQ ID NO:2. --

- 86. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 85 through 98 of PSCA as described in SEQ ID NO:2. --

REMARKS

By way of this Preliminary Amendment, applicants cancelled claims 2-52 and add new claims 53-86. Accordingly, claims 1 and 53-86 are pending.

The amendment to the specification at the paragraph beginning at line 5, page 1, is merely to state the priority information and does not constitute new matter.

The amendment to the specification at the paragraph beginning at line 13, page 6, is merely to add the sequence listing indicator (e.g., SEQ ID NO:) and does not constitute new matter.

The amendment to the specification at the paragraph beginning at line 16, page 6, is merely to add the sequence listing indicator (e.g., SEQ ID NO:) and does not constitute new matter.

Support for new claim 53 can be found in the originally-filed specification at page 26, lines 21-25; page 32, lines 28-29; page 61, lines 19-25.

Support for new claim 54 can be found in the originally-filed specification of 09/564,329 at page 21, lines 29-30.

Support for new claim 55 can be found in the originally-filed specification of 09/564,329 at page 23, lines 4-7.

Support for new claim 56 can be found in the originally-filed specification of 09/564,329 at page 23, lines 4-7.

Support for new claim 57 can be found in the originally-filed specification of 09/564,329 at page 23, lines 4-7.

Support for new claim 58 can be found in the originally-filed specification of 09/564,329 at page 115, lines 15-16.

Support for new claim 59 can be found in the originally-filed specification of 09/564,329 at page 89, lines 7-9.

Support for new claim 60 can be found in the originally-filed specification of 09/564,329 at page 92, lines 27-28.

Support for new claim 61 can be found in the originally-filed specification of 09/564,329 at page 92, lines 28-29.

Support for new claim 62 can be found in the originally-filed specification of 09/564,329 at page 30, line 26.

Support for new claim 63 can be found in the originally-filed specification of 09/564,329 at page 30, line 26.

Support for new claim 64 can be found in the originally-filed specification of 09/564,329 at page 6, lines 18-23; and Figure 3; and page 92, lines 6-7.

Support for new claim 65 can be found in the originally-filed specification of 09/564,329 at page 22, line 24.

Support for new claim 66 can be found in the originally-filed specification of 09/564,329 at page 92, lines 29-30.

Support for new claim 67 can be found in the originally-filed specification of 09/564,329 at page 23, lines 4-7.

Support for new claim 68 can be found in the originally-filed specification of 09/564,329 at page 23, lines 4-7.

Support for new claim 69 can be found in the originally-filed specification of 09/564,329 at page 23, lines 4-7.

Support for new claim 70 can be found in the originally-filed specification of 09/564,329 at page 61, lines 18-19.

Support for new claim 71 can be found in the originally-filed specification of 09/564,329 at page 21, lines 29-30.

Support for new claim 72 can be found in the originally-filed specification of 09/564,329 at page 23, lines 4-7.

Support for new claim 73 can be found in the originally-filed specification of 09/564,329 at page 23, lines 4-7.

Support for new claim 74 can be found in the originally-filed specification of 09/564,329 at page 23, lines 4-7.

Support for new claim 75 can be found in the originally-filed specification of 09/564,329 at page 115, lines 15-16.

Support for new claim 76 can be found in the originally-filed specification of 09/564,329 at page 89, lines 7-9.

Support for new claim 77 can be found in the originally-filed specification of 09/564,329 at page 92, lines 27-28.

Support for new claim 78 can be found in the originally-filed specification of 09/564,329 at page 92, lines 28-29.

Support for new claim 79 can be found in the originally-filed specification of 09/564,329 at page 30, line 26.

Support for new claim 80 can be found in the originally-filed specification of 09/564,329 at page 30, line 26.

Support for new claim 81 can be found in the originally-filed specification of 09/564,329 at page 6, lines 18-23; and Figure 3; and page 92, lines 6-7.

Support for new claim 82 can be found in the originally-filed specification of 09/564,329 at page 22, line 24.

Support for new claim 83 can be found in the originally-filed specification of 09/564,329 at page 92, lines 29-30.

Support for new claim 84 can be found in the originally-filed specification of 09/564,329 at page 23, lines 4-7.